Intravitreal bevacizumab

Intravitreal Injection of Bevacizumab (Avastin) to Treat Posterior Capsule Neovascularization

We report a 64-year-old diabetic woman who developed neovascularization of the posterior capsule 2 years after cataract surgery and intraocular lens implantation. The patient was treated with single injection of 1.25 mg of intravitreal bevacizumab (Avastin) via pars plana. After one week, complete regression of the posterior capsule neovascularization was achieved allowing us to perform Nd: YAG...

Intravitreal bevacizumab for incontinentia pigmenti.

Two eyes of two siblings affected with incontinentia pigmenti having severe proliferative retinopathy are reported. Both cases showed complete resolution of new vessels after a single injection of intravitreal bevacizumab. At 7 months of follow-up, the first case revealed vascularization to the mid-periphery including a vascularized fovea (which was avascular before injection) but recurrence of...

Intravitreal bevacizumab in central serous chorioretinopathy.

OBJECTIVE To evaluate the effect of intravitreal bevacizumab injection in patients with central serous chorioretinopathy (CSCR). STUDY DESIGN Quasi-experimental study. PLACE AND DURATION OF STUDY Layton Rehmatullah Benevolent Trust Eye and Cancer Hospital, Lahore, from July 2010 to April 2011. METHODOLOGY There were 43 eyes of 32 adult patients with CSCR. Patients with choroidal neovascul...

Using intravitreal bevacizumab (Avastin®) – Indian Scenario

Infectious and noninfectious endophthalmitis after intravitreal bevacizumab.

AIMS The aim of this study was to evaluate the rate of infectious and noninfectious endophthalmitis after an intravitreal injection of bevacizumab. METHODS This clinical interventional case-series study included 1218 intravitreal injections of 1.5 mg of bevacizumab consecutively performed for 684 eyes with exudative age-related macular degeneration. Among the injections were 534 reinjections....